Pivotal Phase 3 4WARD clinical trial is evaluating use of oral mavorixafor as monotherapy and in combination with injectable ...

Raleigh: Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of ...

Fostamatinib was approved in 2018 to treat adults with chronic immune thrombocytopenia (ITP) who had an insufficient response ...

Following a pair of similar deals in January and June, Coherus BioSciences has netted itself a hefty chunk of change for the ...

The funding will allow 52North to move its products, including its Neutrocheck point-of-care device, toward commercialization.

In patients with advanced solid tumors, treatment with nemvaleukin with or without Keytruda demonstrated antitumor activity ...

On Wednesday, Cambridge, UK-based 52North, the medtech company focused on transforming urgent care pathways in oncology, ...

Molecular Cellular Pharmacology Graduate Program, University of Wisconsin-Madison, Madison, USA Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan ...

Inc. ("bluebird bio") today announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an outcomes-based agreement for LYFGENIA gene therapy under the Cell and ...

At ESMO 2024, Dr. Andrea Necchi presented the results of an interim analysis of SunRISe-4, noting a pathological complete response rate in the combination arm of 42% and pathologic objective response ...